Contracts › 75N94023F00002
75N94023F00002: Phase I/Ii Dose-Finding, Safety, and Tolerability Study of Daily Rifapentine (RPT) Combined With Isoniazid (INH) (1HP) for Tuberculosis Prevention in Children Two to Less Than 13 Years of Age With and Without Hiv
Awarded to Westat, Inc. by National Institutes of Health (NIH).
$2.2Mobligated
$2.2Mpotential value
31 May 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N94023F00002 |
|---|---|
| Vehicle | 75N94023D00001 |
| Awardee | Westat, Inc. |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NICHD |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Period of performance | 01 June 2023 to 31 May 2027 |
| Potential end | 31 May 2027 |
| Estimated recompete solicitation | ~Q4 2026 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 06 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record